-
Group 3 innate lymphoid cells: A trained Gutkeeper Immunol. Rev. (IF 8.7) Pub Date : 2024-03-16 Nicolas Serafini, James P. Di Santo
SummaryGroup 3 innate lymphoid cells (ILC3s) are tissue‐resident immune lymphocytes that critically regulate intestinal homeostasis, organogenesis, and immunity. ILC3s possess the capacity to “sense” the inflammatory environment within tissues, especially in the context of pathogen challenges that imprints durable non‐antigen‐specific changes in ILC3 function. As such, ILC3s become a new actor in the
-
Epigenetic control of microglial immune responses Immunol. Rev. (IF 8.7) Pub Date : 2024-03-16 Rebekka Scholz, Desirée Brösamle, Xidi Yuan, Marc Beyer, Jonas J. Neher
SummaryMicroglia, the major population of brain‐resident macrophages, are now recognized as a heterogeneous population comprising several cell subtypes with different (so far mostly supposed) functions in health and disease. A number of studies have performed molecular characterization of these different microglial activation states over the last years making use of “omics” technologies, that is transcriptomics
-
Metabolic regulation of type I interferon production Immunol. Rev. (IF 8.7) Pub Date : 2024-03-11 Shane M. O'Carroll, Fiona D. R. Henkel, Luke A. J. O'Neill
SummaryOver the past decade, there has been a surge in discoveries of how metabolic pathways regulate immune cell function in health and disease, establishing the field of immunometabolism. Specifically, pathways such as glycolysis, the tricarboxylic acid (TCA) cycle, and those involving lipid metabolism have been implicated in regulating immune cell function. Viral infections cause immunometabolic
-
Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment Immunol. Rev. (IF 8.7) Pub Date : 2024-03-09 Adnan Moinuddin, Sophie M. Poznanski, Ana L. Portillo, Jonathan K. Monteiro, Ali A. Ashkar
SummaryNatural Killer (NK) cells are a top contender in the development of adoptive cell therapies for cancer due to their diverse antitumor functions and ability to restrict their activation against nonmalignant cells. Despite their success in hematologic malignancies, NK cell‐based therapies have been limited in the context of solid tumors. Tumor cells undergo various metabolic adaptations to sustain
-
Maternal‐driven immune education in offspring Immunol. Rev. (IF 8.7) Pub Date : 2024-03-06 Krist Antunes Fernandes, Ai Ing Lim
SummaryMaternal environmental exposures, particularly during gestation and lactation, significantly influence the immunological development and long‐term immunity of offspring. Mammalian immune systems develop through crucial inputs from the environment, beginning in utero and continuing after birth. These critical developmental windows are essential for proper immune system development and, once closed
-
Functional neutrophil disorders: Chronic granulomatous disease and beyond Immunol. Rev. (IF 8.7) Pub Date : 2024-03-02 Christa S. Zerbe, Steven M. Holland
SummarySince their description by Metchnikoff in 1905, phagocytes have been increasingly recognized to be the entities that traffic to sites of infection and inflammation, engulf and kill infecting organisms, and clear out apoptotic debris all the while making antigens available and accessible to the lymphoid organs for future use. Therefore, phagocytes provide the gateway and the first check in host
-
No time to die: Epigenetic regulation of natural killer cell survival Immunol. Rev. (IF 8.7) Pub Date : 2024-03-01 Leen Hermans, Timothy E. O'Sullivan
SummaryNK cells are short‐lived innate lymphocytes that can mediate antigen‐independent responses to infection and cancer. However, studies from the past two decades have shown that NK cells can acquire transcriptional and epigenetic modifications during inflammation that result in increased survival and lifespan. These findings blur the lines between the innate and adaptive arms of the immune system
-
ITAM‐based receptors in natural killer cells Immunol. Rev. (IF 8.7) Pub Date : 2024-02-27 Oscar A. Aguilar, Lam‐Kiu Fong, Lewis L. Lanier
SummaryThe ability of cells of the immune system to acquire features such as increased longevity and enhanced secondary responses was long thought to be restricted to cells of the adaptive immune system. Natural killer (NK) cells have challenged this notion by demonstrating that they can also gain adaptive features. This has been observed in both humans and mice during infection with cytomegalovirus
-
Functional genomics in inborn errors of immunity Immunol. Rev. (IF 8.7) Pub Date : 2024-02-08 Charlotte Hurabielle, Taylor N. LaFlam, Melissa Gearing, Chun Jimmie Ye
Inborn errors of immunity (IEI) comprise a diverse spectrum of 485 disorders as recognized by the International Union of Immunological Societies Committee on Inborn Error of Immunity in 2022. While IEI are monogenic by definition, they illuminate various pathways involved in the pathogenesis of polygenic immune dysregulation as in autoimmune or autoinflammatory syndromes, or in more common infectious
-
Inborn errors of immunity illuminate mechanisms of human immunology and pave the road to precision medicine Immunol. Rev. (IF 8.7) Pub Date : 2024-02-02 Elena W. Y. Hsieh, Alexandre Bolze, Joseph D. Hernandez
The Yellow Brick Road leads Dorothy through Oz to the Emerald City—a luminescent green metropolis where she hopes to meet the great and powerful Wizard. The Emerald City is the destination of Dorothy's journey, where desires become reality. Arguably, the “Emerald City” for most physician-scientists caring for patients with inborn errors of immunity (IEI) is to apply effective therapies that target
-
Severe combined immunodeficiency diagnosis and genetic defects Immunol. Rev. (IF 8.7) Pub Date : 2024-01-29 Carolina Sanchez Aranda, Mariana Pimentel Gouveia-Pereira, Celso Jose Mendanha da Silva, Maria Candida Faria Varanda Rizzo, Edson Ishizuka, Edgar Borges de Oliveira, Antonio Condino-Neto
Severe combined immunodeficiency (SCID) is a rare and life-threatening genetic disorder that severely impairs the immune system's ability to defend the body against infections. Often referred to as the “bubble boy” disease, SCID gained widespread recognition due to the case of David Vetter, a young boy who lived in a sterile plastic bubble to protect him from germs. SCID is typically present at birth
-
Cover Image Immunol. Rev. (IF 8.7) Pub Date : 2024-01-25 Carlos Luri-Rey, Gabriel Gomis, Javier Glez-Vaz, Almudena Manzanal, Ana Martinez Riaño, Maria E. Rodriguez Ruiz, Alvaro Teijeira
-
Gene regulation in inborn errors of immunity: Implications for gene therapy design and efficacy Immunol. Rev. (IF 8.7) Pub Date : 2024-01-17 Hana Y. Ghanim, Matthew H. Porteus
Inborn errors of immunity (IEI) present a unique paradigm in the realm of gene therapy, emphasizing the need for precision in therapeutic design. As gene therapy transitions from broad-spectrum gene addition to careful modification of specific genes, the enduring safety and effectiveness of these therapies in clinical settings have become crucial. This review discusses the significance of IEIs as foundational
-
Primary and secondary defects of the thymus Immunol. Rev. (IF 8.7) Pub Date : 2024-01-16 Sarah S. Dinges, Kayla Amini, Luigi D. Notarangelo, Ottavia M. Delmonte
The thymus is the primary site of T-cell development, enabling generation, and selection of a diverse repertoire of T cells that recognize non-self, whilst remaining tolerant to self- antigens. Severe congenital disorders of thymic development (athymia) can be fatal if left untreated due to infections, and thymic tissue implantation is the only cure. While newborn screening for severe combined immune
-
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023 Immunol. Rev. (IF 8.7) Pub Date : 2024-01-09 Paul Bastard, Adrian Gervais, Tom Le Voyer, Quentin Philippot, Aurélie Cobat, Jérémie Rosain, Emmanuelle Jouanguy, Laurent Abel, Shen-Ying Zhang, Qian Zhang, Anne Puel, Jean-Laurent Casanova
Human autoantibodies (auto-Abs) neutralizing type I IFNs were first discovered in a woman with disseminated shingles and were described by Ion Gresser from 1981 to 1984. They have since been found in patients with diverse conditions and are even used as a diagnostic criterion in patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1). However, their apparent lack of association with viral
-
The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity Immunol. Rev. (IF 8.7) Pub Date : 2023-12-25 Christopher D. Putnam, Lori Broderick, Hal M. Hoffman
From studies of individual families to global collaborative efforts, the NLRP3 inflammasome is now recognized to be a key regulator of innate immunity. Activated by a panoply of pathogen-associated and endogenous triggers, NLRP3 serves as an intracellular sensor that drives carefully coordinated assembly of the inflammasome, and downstream inflammation mediated by IL-1 and IL-18. Initially discovered
-
Understanding very early onset inflammatory bowel disease (VEOIBD) in relation to inborn errors of immunity Immunol. Rev. (IF 8.7) Pub Date : 2023-12-19 Caroline H. T. Hall, Edwin F. de Zoeten
Inflammatory bowel diseases (IBD) are multifactorial diseases which are caused by the combination of genetic predisposition, exposure factors (environmental and dietary), immune status, and dysbiosis. IBD is a disease which presents at any age, ranging from newborns to the elderly. The youngest of the pediatric IBD population have a more unique presentation and clinical course and may have a different
-
Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology Immunol. Rev. (IF 8.7) Pub Date : 2023-12-15 Michael B. Jordan
Hemophagocytic lymphohistiocytosis (HLH) is a disorder that has been recognized since the middle of the last century. In recent decades, increasing understanding of the genetic roots and pathophysiology of HLH has led to improved diagnosis and treatment of this once universally fatal disorder. HLH is best conceptualized as a maladaptive state of excessive T cell activation driving life-threatening
-
Mechanisms of programmed cell death Immunol. Rev. (IF 8.7) Pub Date : 2023-12-14 Tian Li, Guido Kroemer
The present volume of Immunological Reviews deals with the mechanisms of programmed cell death, obviously from an immunological perspective. What are the consequences of cell death on the organism and, in particular, on the immune recognition of stressed and dying cells? The long-distance effects of therapeutic manipulations resulting in the death of cancer cells are surprisingly vast, as this has
-
Decoding immunogenic cell death from a dendritic cell perspective Immunol. Rev. (IF 8.7) Pub Date : 2023-12-13 Sophie Janssens, Sofie Rennen, Patrizia Agostinis
Dendritic cells (DCs) are myeloid cells bridging the innate and adaptive immune system. By cross-presenting tumor-associated antigens (TAAs) liberated upon spontaneous or therapy-induced tumor cell death to T cells, DCs occupy a pivotal position in the cancer immunity cycle. Over the last decades, the mechanisms linking cancer cell death to DC maturation, have been the focus of intense research. Growing
-
Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research Immunol. Rev. (IF 8.7) Pub Date : 2023-12-12 Takaki Asano, Kosuke Noma, Yoko Mizoguchi, Shuhei Karakawa, Satoshi Okada
Germline human heterozygous STAT1 gain-of-function (GOF) variants were first discovered a common cause of chronic mucocutaneous candidiasis (CMC) in 2011. Since then, numerous STAT1 GOF variants have been identified. A variety of clinical phenotypes, including fungal, viral, and bacterial infections, endocrine disorders, autoimmunity, malignancy, and aneurysms, have recently been revealed for STAT1
-
Proteasome disorders and inborn errors of immunity Immunol. Rev. (IF 8.7) Pub Date : 2023-12-09 M. Cecilia Poli
Inborn errors of immunity (IEI) or primary immune deficiencies (PIDD) are caused by variants in genes encoding for molecules that are relevant to the innate or adaptive immune response. To date, defects in more than 450 different genes have been identified as causes of IEI, causing a constellation of heterogeneous clinical manifestations ranging from increased susceptibility to infection, to autoimmunity
-
From Mendel to mycoses: Immuno-genomic warfare at the human–fungus interface Immunol. Rev. (IF 8.7) Pub Date : 2023-12-08 Donald C. Vinh
Fungi are opportunists: They particularly require a defect of immunity to cause severe or disseminated disease. While often secondary to an apparent iatrogenic cause, fungal diseases do occur in the absence of one, albeit infrequently. These rare cases may be due to an underlying genetic immunodeficiency that can present variably in age of onset, severity, or other infections, and in the absence of
-
Inborn errors of immunity: A field without frontiers Immunol. Rev. (IF 8.7) Pub Date : 2023-12-08 Giorgia Bucciol, Selket Delafontaine, Isabelle Meyts, Cecilia Poli
The study of primary immunodeficiencies or inborn errors of immunity continues to drive our knowledge of the function of the human immune system. From the outset, the study of inborn errors has focused on unraveling genetic etiologies and molecular mechanisms. Aided by the continuous growth in genetic diagnostics, the field has moved from the study of an infection dominated phenotype to embrace and
-
Pyroptosis in glioma: Current management and future application Immunol. Rev. (IF 8.7) Pub Date : 2023-12-08 Zeshang Guo, Zhenjin Su, Ying Wei, Xingmei Zhang, Xinyu Hong
Glioma, the predominant form of central nervous system (CNS) malignancies, presents a significant challenge due to its high prevalence and low 5-year survival rate. The efficacy of current treatment methods is limited by the presence of the blood–brain barrier, the immunosuppressive microenvironment, and other factors. Immunotherapy has emerged as a promising approach, as it can overcome the blood–brain
-
The immune system in Down Syndrome: Autoimmunity and severe infections Immunol. Rev. (IF 8.7) Pub Date : 2023-12-05 Meredith Ramba, Dusan Bogunovic
Over 200,000 individuals in the United States alone live with Down Syndrome (DS), the most common genetic disorder associated with intellectual disability. DS has a constellation of features across the body, including dysregulation of the immune system. Individuals with DS have both a higher frequency of autoimmunity and more severe infections than the general population, highlighting the importance
-
Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decades Immunol. Rev. (IF 8.7) Pub Date : 2023-11-30 Donald B. Kohn
Severe combined immune deficiency due to adenosine deaminase deficiency (ADA SCID) is an inborn error of immunity with pan-lymphopenia, due to accumulated cytotoxic adenine metabolites. ADA SCID has been treated using gene therapy with a normal human ADA gene added to autologous hematopoietic stem cells (HSC) for over 30 years. Iterative improvements in vector design, HSC processing methods, and clinical
-
Common variable immunodeficiency, cross currents, and prevailing winds Immunol. Rev. (IF 8.7) Pub Date : 2023-11-28 Neil Romberg, Carole Le Coz
Common variable immunodeficiency (CVID) is a heterogenous disease category created to distinguish late-onset antibody deficiencies from early-onset diseases like agammaglobulinemia or more expansively dysfunctional combined immunodeficiencies. Opinions vary on which affected patients should receive a CVID diagnosis which confuses clinicians and erects reproducibility barriers for researchers. Most
-
Rubella virus chronic inflammatory disease and other unusual viral phenotypes in inborn errors of immunity Immunol. Rev. (IF 8.7) Pub Date : 2023-11-27 Gonench Kilich, Ludmila Perelygina, Kathleen E. Sullivan
Infectious susceptibility is a component of many inborn errors of immunity. Nevertheless, antibiotic use is often used as a surrogate in history taking for infectious susceptibility, thereby disadvantaging patients who present with viral infections as their phenotype. Further complicating clinical evaluations are unusual manifestations of viral infections which may be less familiar that the typical
-
FOXP3 deficiency, from the mechanisms of the disease to curative strategies Immunol. Rev. (IF 8.7) Pub Date : 2023-11-23 Simon Borna, Eric Meffre, Rosa Bacchetta
FOXP3 gene is a key transcription factor driving immune tolerance and its deficiency causes immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome (IPEX), a prototypic primary immune regulatory disorder (PIRD) with defective regulatory T (Treg) cells. Although life-threatening, the increased awareness and early diagnosis have contributed to improved control of the disease. IPEX currently
-
The trajectory of human B-cell function, immune deficiency, and allergy revealed by inborn errors of immunity Immunol. Rev. (IF 8.7) Pub Date : 2023-11-20 Stuart G. Tangye, Joseph Mackie, Karrnan Pathmanandavel, Cindy S. Ma
The essential role of B cells is to produce protective immunoglobulins (Ig) that recognize, neutralize, and clear invading pathogens. This results from the integration of signals provided by pathogens or vaccines and the stimulatory microenvironment within sites of immune activation, such as secondary lymphoid tissues, that drive mature B cells to differentiate into memory B cells and antibody (Ab)-secreting
-
The role of exosomes in cancer-related programmed cell death Immunol. Rev. (IF 8.7) Pub Date : 2023-11-10 Xin Li, Zuoqian Jing, Xuejie Li, Lei Liu, Xiang Xiao, Yifan Zhong, Zihan Ren
Cancer arises from the growth and division of uncontrolled erroneous cells. Programmed cell death (PCD), or regulated cell death (RCD), includes natural processes that eliminate damaged or abnormal cells. Dysregulation of PCD is a hallmark of cancer, as cancer cells often evade cell death and continue to proliferate. Exosomes nanoscale extracellular vesicles secreted by different types of cells carrying
-
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy Immunol. Rev. (IF 8.7) Pub Date : 2023-11-08 Raquel S. Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Jannes Govaerts, Stefan Naulaerts, Abhishek D. Garg
The cellular stress and immunity cycle is a cornerstone of organismal homeostasis. Stress activates intracellular and intercellular communications within a tissue or organ to initiate adaptive responses aiming to resolve the origin of this stress. If such local measures are unable to ameliorate this stress, then intercellular communications expand toward immune activation with the aim of recruiting
-
Targeting ferroptosis in gastric cancer: Strategies and opportunities Immunol. Rev. (IF 8.7) Pub Date : 2023-10-30 Jiahan Le, Guangzhao Pan, Che Zhang, Yitao Chen, Amit K. Tiwari, Jiang-Jiang Qin
Ferroptosis is a novel form of programmed cell death morphologically, genetically, and biochemically distinct from other cell death pathways and characterized by the accumulation of iron-dependent lipid peroxides and oxidative damage. It is now understood that ferroptosis plays an essential role in various biological processes, especially in the metabolism of iron, lipids, and amino acids. Gastric
-
Cell type-specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases Immunol. Rev. (IF 8.7) Pub Date : 2023-10-28 Ying Guo, Jin Zhou, Yaqi Wang, Xueliang Wu, Yakui Mou, Xicheng Song
Necroptosis is generally considered as an inflammatory cell death form. The core regulators of necroptotic signaling are receptor-interacting serine–threonine protein kinases 1 (RIPK1) and RIPK3, and the executioner, mixed lineage kinase domain-like pseudokinase (MLKL). Evidence demonstrates that necroptosis contributes profoundly to inflammatory respiratory diseases that are common public health problem
-
Golden age of immunoengineering Immunol. Rev. (IF 8.7) Pub Date : 2023-10-23 Wilson W. Wong, Wendell A. Lim
1 INTRODUCTION Immunology has long been the source of many significant medical breakthroughs, from vaccines for infections to therapeutics for cancer, autoimmunity, and transplant rejection. Indeed, the only diseases we have successfully eradicated, for example, smallpox and polio, were achieved through our understanding of the immune system. Furthermore, the immune system often plays an unexpected
-
Phagocytic clearance of dying cells and its implications Immunol. Rev. (IF 8.7) Pub Date : 2023-10-19 Kodi S. Ravichandran
It is estimated that an average adult human turns over roughly 330 ± 20 billion cells every day as part of healthy living.1, 2 This translates to 0.4% of our body mass. Such a large number for cell turnover then begs the question—what are these cells and why? The reasons for this are multi-factorial. First, there are cells in the body that have a finite life span, such as neutrophils (~1 day) and erythrocytes
-
A variety of death modes of neutrophils and their role in the etiology of autoimmune diseases Immunol. Rev. (IF 8.7) Pub Date : 2023-10-18 Yanhong Li, Yinlan Wu, Jingang Huang, Xue Cao, Qiyuan An, Yun Peng, Yi Zhao, Yubin Luo
Neutrophils are important in the context of innate immunity and actively contribute to the progression of diverse autoimmune disorders. Distinct death mechanisms of neutrophils may exhibit specific and pivotal roles in autoimmune diseases and disease pathogenesis through the orchestration of immune homeostasis, the facilitation of autoantibody production, the induction of tissue and organ damage, and
-
PANoptosis: Mechanisms, biology, and role in disease Immunol. Rev. (IF 8.7) Pub Date : 2023-10-12 Xu Sun, Yanpeng Yang, Xiaona Meng, Jia Li, Xiaoli Liu, Huaimin Liu
Cell death can be executed through distinct subroutines. PANoptosis is a unique inflammatory cell death modality involving the interactions between pyroptosis, apoptosis, and necroptosis, which can be mediated by multifaceted PANoptosome complexes assembled via integrating components from other cell death modalities. There is growing interest in the process and function of PANoptosis. Accumulating
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming Immunol. Rev. (IF 8.7) Pub Date : 2023-10-11 Carlos Luri-Rey, Gabriel Gomis, Javier Glez-Vaz, Almudena Manzanal, Ana Martinez Riaño, Maria E. Rodriguez Ruiz, Alvaro Teijeira, Ignacio Melero
Antigen cross-priming of CD8+ T cells is a critical process necessary for the effective expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy tumor cells. The cross-presentation of tumor antigens to cross-prime CD8+ T cells is mainly mediated, if not only, by a subset of professional antigen-presenting cells termed type-1 conventional dendritic cells (cDC1). The
-
Specialized pro-resolving mediators enhance the clearance of dead cells Immunol. Rev. (IF 8.7) Pub Date : 2023-10-03 Gabrielle Fredman, Sayeed Khan
The failure to resolve inflammation underpins to several prevalent diseases, like atherosclerosis, and so identifying ways to boost resolution is unmet clinical needs. The resolution of inflammation is governed by several factors such as specialized pro-resolving mediators (SPMs) that counter-regulate pro-inflammatory pathways and promote tissue repair without compromising host defense. A major function
-
Copper homeostasis and cuproptosis in cancer immunity and therapy Immunol. Rev. (IF 8.7) Pub Date : 2023-09-16 Wei-Qing Liu, Wan-Rong Lin, Li Yan, Wen-Hao Xu, Jun Yang
Copper is an essential nutrient for maintaining enzyme activity and transcription factor function. Excess copper results in the aggregation of lipoylated dihydrolipoamide S-acetyltransferase (DLAT), which correlates to the mitochondrial tricarboxylic acid (TCA) cycle, resulting in proteotoxic stress and eliciting a novel cell death modality: cuproptosis. Cuproptosis exerts an indispensable role in
-
NETosis: Sculpting tumor metastasis and immunotherapy Immunol. Rev. (IF 8.7) Pub Date : 2023-09-15 Yanyan Hu, Houhong Wang, Yang Liu
The process of neutrophil extracellular traps (NETs) formation, called NETosis, is a peculiar death modality of neutrophils, which was first observed as an immune response against bacterial infection. However, recent work has revealed the unique biology of NETosis in facilitating tumor metastatic process. Neutrophil extracellular traps released by the tumor microenvironment (TME) shield tumor cells
-
“Hurdles race for CAR T-cell therapy in digestive tract cancer” Immunol. Rev. (IF 8.7) Pub Date : 2023-09-11 Marie-Noelle Kronig, Marc Wehrli, Diego Salas-Benito, Marcela V. Maus
Digestive tract cancers (DTC) belong to the most investigated family of tumors. The incidence, prevalence, and mortality rate of DTC remain high, especially for patients with pancreatic cancer. Even though immunotherapy such as immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid cancer types, ICI are still restricted to a very small group of patients and seem to be more efficacious
-
Stress/cell death pathways, neuroinflammation, and neuropathic pain Immunol. Rev. (IF 8.7) Pub Date : 2023-09-08 Lu Li, Tian Li, Xinyu Qu, Guangwei Sun, Qi Fu, Guang Han
Neuropathic pain is a common and debilitating modality of chronic pain induced by a lesion or disease of the somatosensory nervous system. Albeit the elucidation of numerous pathophysiological mechanisms and the development of potential treatment compounds, safe and reliable therapies of neuropathic pain remain poor. Multiple stress/cell death pathways have been shown to be implicated in neuroinflammation
-
Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy Immunol. Rev. (IF 8.7) Pub Date : 2023-09-08 Shutong Li, Aoxue Wang, Yongya Wu, Shengyuan He, Wen Shuai, Min Zhao, Yumeng Zhu, Xiuying Hu, Yubin Luo, Guan Wang
Non-small-cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small-molecule compounds
-
Molecular determinants of immunogenic cell death elicited by radiation therapy Immunol. Rev. (IF 8.7) Pub Date : 2023-09-07 Claudia Galassi, Vanessa Klapp, Takahiro Yamazaki, Lorenzo Galluzzi
Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses against dead cell-associated antigens, provided that (1) said antigens are not perfectly covered by central tolerance (antigenicity), (2) cell death occurs along with the emission of immunostimulatory cytokines and damage-associated molecular patterns (DAMPs) that actively engage immune effector mechanisms (adjuvanticity)
-
Type I interferon and cancer Immunol. Rev. (IF 8.7) Pub Date : 2023-09-04 Peter Holicek, Emma Guilbaud, Vanessa Klapp, Iva Truxova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova
Type I interferon (IFN) is a class of proinflammatory cytokines with a dual role on malignant transformation, tumor progression, and response to therapy. On the one hand, robust, acute, and resolving type I IFN responses have been shown to mediate prominent anticancer effects, reflecting not only their direct cytostatic/cytotoxic activity on (at least some) malignant cells, but also their pronounced
-
The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients Immunol. Rev. (IF 8.7) Pub Date : 2023-08-26 Alexandra-Chloé Villani
1 INTRODUCTION Immune checkpoint inhibitors (ICIs), including antibodies targeting anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1), anti-programmed cell death 1 ligand 1 (PD-L1) have revolutionized cancer treatment.1, 2 Both PD-1 and CTLA-4 are upregulated upon T-cell activation and function to inhibit peripheral T-cell responses. These receptors maintain immune
-
Antibody-mediated phagocytosis in cancer immunotherapy Immunol. Rev. (IF 8.7) Pub Date : 2023-08-21 Carly M. Van Wagoner, Fátima Rivera-Escalera, Nydia C. Jaimes-Delgadillo, Charles C. Chu, Clive S. Zent, Michael R. Elliott
Unconjugated monoclonal antibodies (mAbs) have revolutionized the treatment of many types of cancer. Some of these mAbs promote the clearance of malignant cells via direct cytotoxic effects. More recently, antibody-dependent cellular phagocytosis (ADCP) has been appreciated as a major mechanism of action for a number of widely used mAbs, including anti-CD20 (rituximab, obinutuzumab), anti-HER2 (trastuzumab)
-
TAM receptors in phagocytosis: Beyond the mere internalization of particles Immunol. Rev. (IF 8.7) Pub Date : 2023-08-19 Tal Burstyn-Cohen, Roberta Fresia
TYRO3, AXL, and MERTK constitute the TAM family of receptor tyrosine kinases, activated by their ligands GAS6 and PROS1. TAMs are necessary for adult homeostasis in the immune, nervous, reproductive, skeletal, and vascular systems. Among additional cellular functions employed by TAMs, phagocytosis is central for tissue health. TAM receptors are dominant in providing phagocytes with the molecular machinery
-
Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells Immunol. Rev. (IF 8.7) Pub Date : 2023-08-19 Peng Liu, Liwei Zhao, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
The search for immunostimulatory drugs applicable to cancer immunotherapy may profit from target-agnostic methods in which agents are screened for their functional impact on immune cells cultured in vitro without any preconceived idea on their mode of action. We have built a synthetic mini-immune system in which stressed and dying cancer cells (derived from standardized cell lines) are confronted with
-
Cover Image Immunol. Rev. (IF 8.7) Pub Date : 2023-08-17 Zsolt Czimmerer, Laszlo Nagy
The cover image is based on the Invited Review Epigenomic regulation of macrophage polarization: Where do the nuclear receptors belong? by Zsolt Czimmerer et al.,https://doi.org/10.1111/imr.13209
-
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application Immunol. Rev. (IF 8.7) Pub Date : 2023-08-18 François Ghiringhelli, Cédric Rébé
Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, a high proportion of patients do not respond. Moreover, some types of cancers are refractory to these treatments. Thus, the need to find predictive biomarkers of efficacy and to evaluate the association with other treatments, such as chemotherapy or radiotherapy, appears to be essential. Because ICIs
-
Understanding the diversity and dynamics of in vivo efferocytosis: Insights from the fly embryo Immunol. Rev. (IF 8.7) Pub Date : 2023-08-17 Rosalind Heron, Clelia Amato, Will Wood, Andrew J. Davidson
The clearance of dead and dying cells, termed efferocytosis, is a rapid and efficient process and one that is critical for organismal health. The extraordinary speed and efficiency with which dead cells are detected and engulfed by immune cells within tissues presents a challenge to researchers who wish to unravel this fascinating process, since these fleeting moments of uptake are almost impossible
-
Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash” Immunol. Rev. (IF 8.7) Pub Date : 2023-08-15 Blair S. Allais, Christopher J. Fay, Daniel Y. Kim, Yevgeniy R. Semenov, Nicole R. LeBoeuf
Uncoupling toxicity from therapeutic effect lies at the foundation of the current state of the field of cutaneous immune-related adverse events to immune checkpoint inhibitor therapy. This will be achieved through understanding the drivers of toxicity, tumor response, and resistance via large, well-powered population-level studies, institutional cohort data, and cellular-level data. Increasing diagnostic
-
Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses Immunol. Rev. (IF 8.7) Pub Date : 2023-08-14 Steven M. Blum, Sherin J. Rouhani, Ryan J. Sullivan
Immune checkpoint inhibitors (ICIs) are potentially life-saving cancer therapies that can trigger immune-related adverse events (irAEs). irAEs can impact any organ and range in their presentation from mild side effects to life-threatening complications. The relationship between irAEs and antitumor immune responses is nuanced and may depend on the irAE organ, the tumor histology, and the patient. While
-
Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events Immunol. Rev. (IF 8.7) Pub Date : 2023-08-10 Morgan L. Cina, Jessica Venegas, Arabella Young
Cancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad and variable array of immune-related adverse events (irAEs). With increasing clinical use of ICIs, defining the mechanism for irAE development is more critical than ever. However, it currently remains challenging to predict when these irAEs occur and which organ may be affected, and for many of the more severe
-
Clearance phagocytosis by the retinal pigment epithelial during photoreceptor outer segment renewal: Molecular mechanisms and relation to retinal inflammation Immunol. Rev. (IF 8.7) Pub Date : 2023-08-09 Stephanie A. Lieffrig, Gavin Gyimesi, Yingyu Mao, Silvia C. Finnemann
Mammalian photoreceptor outer segment renewal is a highly coordinated process that hinges on timed cell signaling between photoreceptor neurons and the adjacent retinal pigment epithelial (RPE). It is a strictly rhythmic, synchronized process that underlies in part circadian regulation. We highlight findings from recently developed methods that quantify distinct phases of outer segment renewal in retinal
-
Hijacking homeostasis: Regulation of the tumor microenvironment by apoptosis Immunol. Rev. (IF 8.7) Pub Date : 2023-08-08 Christopher D. Gregory
Cancers are genetically driven, rogue tissues which generate dysfunctional, obdurate organs by hijacking normal, homeostatic programs. Apoptosis is an evolutionarily conserved regulated cell death program and a profoundly important homeostatic mechanism that is common (alongside tumor cell proliferation) in actively growing cancers, as well as in tumors responding to cytotoxic anti-cancer therapies